Modulation of very low density lipoprotein production and clearance contributes to age- and gender-dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice by Vlijmen, B.J.M. van et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Modulation of Very Low Density Lipoprotein Production and Clearance 
Contributes to Age- and Gender-dependent Hyperlipoproteinemia in 
Apolipoprotein E3-Leiden Transgenic Mice
Bart J.M. van Vlijmen,* H. Belinda van’t Hof,* Marc J.T.M. Moi,* Hans van der Boom,* André van der Zee,§ Rune R. Frants,5 
Marten H. Hofker,§ and Louis M. Havekes*
*TNO Prevention and Health, Gaubius Laboratory, Leiden; ^Department o f Medicine, Division of General Internal Medicine, University 
Hospital Nijmegen, 6500 HB Nijmegen; §Department of Human Genetics, Leiden University, 2301 CE Leiden, The Netherlands
Abstract
Apolipoprotein E3-Leiden (APOE* 3-Leiden) transgenic 
mice have been studied to identify factors modulating chy­
lomicron and VLDL remnant lipoprotein metabolism. 
Transient elevated levels of VLDL/LDL-sized lipoproteins 
occurred in these mice with maximal levels during the pe­
riod of rapid growth (optimum at 45 d of age). After about 
100 d of age, serum cholesterol and triglyceride levels stabi­
lized to slightly elevated levels as compared to control mice. 
The expression of the APOE*3-Leiden transgene was not 
age-dependent. In young mice the in vivo hepatic produc­
tion of VLDL-triglycerides was 50% increased as compared 
to older mice. This is sustained by in vivo VLDL-apo B 
turnover studies showing increased (75%) VLDL-apo B se­
cretion rates in young mice, whereas the VLDL-apo B clear­
ance rate appeared not to be age dependent.
On a high fat/cholesterol diet, females displayed signifi­
cantly higher cholesterol levels than males (10 versus 7.0 
mmol/liter, respectively). Serum levels of VLDL/LDL sized 
lipoproteins increased upon administration of estrogens, 
whereas administration of testosterone gave the opposite re­
sult. As compared to male mice, in female mice the hepatic 
VLDL-triglyceride production rate was significantly ele­
vated. Injection of estrogen in males also resulted in in­
creased VLDL-triglyceride production, although not statis­
tically significant. In vivo VLDL-apo B turnover experiments 
showed that the VLDL secretion rate tended to be higher in 
females. Although, the fractional catabolic rate of VLDL- 
apo B is not different between males and females, adminis­
tration of estrogens in males resulted in a decreased clear­
ance rate of VLDL, whereas administration of testosterone 
in females resulted in an increased clearance rate of VLDL. 
The latter presumably due to an inhibiting effect of tes­
tosterone on the expression of the APOE* 3-Leiden transgene.
We conclude that hyperlipidemia in APOE* 3-Leiden 
transgenic mice is strongly affected by age via its effect on 
hepatic VLDL production rate, whereas gender influences 
hyperlipidemia by modulating both hepatic VLDL pro due-
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Introduction
In Western society people spend most of their life span under 
nonfasting conditions, As a result, there is a continuous release 
into the circulation of newly synthesized intestinal and hepatic 
lipoproteins, i.e., chylomicrons and VLDL lipoproteins. Nor­
mally, the remnants of these lipoproteins are rapidly removed 
from the circulation via receptor-mediated uptake in the liver. 
Apo E is a structural component of these remnant lipoproteins 
and serves as a ligand in the receptor mediated uptake by the 
liver (1, 2). In patients suffering from familial dysbetalipopro­
teinemia (FD),1 a defective apo E leads to impaired hepatic 
uptake of remnant lipoproteins (1). The consequent accumula­
tion of these lipoproteins leads to a predisposition of these pa­
tients to coronary and/or peripheral atherosclerosis (1,3).
Several in vivo and in vitro studies have demonstrated the 
unequivocal role of apo E in remnant lipoprotein metabolism 
(4, 5). However, in homozygous carriers of the mutant 
APOE*2(Argl58-»Cys) allele, the presence of binding defec­
tive apo E2 does not explicitly result in the accumulation of 
remnant lipoproteins. Obviously, other environmental or ge­
netic factors interfere with remnant metabolism (1).
In humans, heterozygosity for the rare mutant APOE* 3- 
Leiden allele is also associated with an accumulation of rem­
nant lipoproteins due to an impaired remnant clearance, de­
spite the presence of normal apo E (6). Thus, in carriers of the 
apo E3-Leiden mutation, FD is inherited in a dominant fash­
ion although also in this case, additional environmental and 
genetic factors do modulate the severity of the disease.
Because of heterogeneity in environmental and genetic 
background, these additional factors can hardly be studied in 
humans. Therefore, to elucidate subtle factors that may modu­
late the metabolism of remnant lipoproteins, a suitable experi­
mental animal model is required. Experimental animals, like 
inbred mice and rats, efficiently remove remnant lipoproteins, 
even under severe dietary stress conditions (7) and are thus 
less suitable for these studies. Recently, we reported that 
transgenic mice expressing the human APOE*3-Leiden muta­
tion also demonstrate a hyperlipidemic phenotype (8). Fur­
thermore, in these mice, severe hyperlipidemia was observed 
after feeding high fat/cholesterol-containing diets which posi­
tively correlated with the level of expression of the transgene
1. Abbreviations used in this paper: FCR, fractional catabolic rate; 
FD , familial dysbetalipoproteinemia; HFC, high fat/cholesterol; SR, 
secretion rate.
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(9). In addition, on high fat/cholesterol-containing diets the 
high expressing lines developed atherosclerotic lesions of 
which the severity was positively correlated with serum levels 
of cholesterol-rich remnant lipoproteins. Thus, also in these 
transgenic mice apo E3-Leiden behaves like a dominant trait 
in the accumulation of remnant lipoproteins.
We reasoned that APOE*3-Leiden mice display a defect in 
plasma clearance of remnant lipoproteins which allows us to 
study the effect of more subtle factors involved in remnant me­
tabolism under highly standardized conditions. The present 
study shows that in APOE*3-Leiden transgenic mice the 
plasma level of VLDL remnants is strongly influenced by age 
and gender related factors. Age appeared to affect the hepatic 
VLDL production rate, whereas gender modulates both the 
VLDL production and clearance rate.
Methods
Animals. Transgenic mice of line No. 2, heterozygous for the expres­
sion of the human A PO  E*3-Leiden and human APOC1 gene, were 
used (8). Transgenic and nontransgenic littermates were obtained by 
breeding with C57BL/6J mice (The Broekman Institute bv, Someren, 
The Netherlands). Mice of the F5 and F6 generation were included in 
the trials. Transgenic mice were identified by sandwich ELISA  for 
the presence of human apo E in the serum (for method see below). 
Immediately after weaning (at age 25 d) mice were equally divided 
into two groups, consisting of female and male transgenic or non- 
transgenic mice. One group of mice was fed a regular mouse diet 
(SRM-A; Hope Farms, Woerden, The Netherlands), and the other 
group of mice was fed a semisynthetic high fat/cholesterol (HFC) 
diet. This H FC diet is a basic semisynthetic diet, which was composed 
essentially according to Nishina et al, (7), supplemented with cocoa 
butter (15%, by wt) and cholesterol (0.25%, by wt) and was pur­
chased from Hope Farms. Mice were housed under standard condi­
tions in conventional cages and given free access to food and water. 
None of the transgenic or nontransgenic mice were lost during the study.
Lipid and lipoprotein analysis. After a 12-h fasting period, mice 
were weighed and ^  50 jxl of blood was obtained from each individ­
ual mouse through tail bleeding. Blood samples were taken at differ­
ent time points as indicated in the figures for both diets. Total serum 
cholesterol and triglyceride levels (without measuring free glycerol) 
were measured enzymatically using commercially available kits (No. 
236691; Boehringer Mannheim, Mannheim, Germ any and No. 337-B; 
Sigma Chemical Co., St. Louis, MO).
For size fractionation of lipoproteins, some 200 fxl of pooled se­
rum (from at least 12 mice), was injected onto a 25 ml Superose 6B 
column (Pharmacia Fine Chemicals, Uppsala, Sweden) connected to 
an HPLC pump system and eluted at a constant flow rate of 0,5 ml/ 
min with PBS, pH 7.4. The effluent was collected in 0.5-ml fractions. 
Cholesterol and triglyceride concentrations in lipoprotein fractions 
were measured enzymatically, using kits No. 236691 and 701904 
(Boehringer Mannheim), respectively.
Human A p o  E3-Leiden protein measurements. Human apo E  con­
centrations were measured by sandwich ELISA . Affinity purified 
polyclonal goat anti-human apo E antibodies were used for coating. 
Affinity purified polyclonal rabbit anti-hum an apo E  antibodies were 
used as second antibodies. Thereafter, the plates were incubated with 
swine anti-rabbit IgG antibodies conjugated to horseradish peroxi­
dase. Finally, horseradish peroxidase detection was performed using 
horseradish peroxidase substrate tetramethylbenzidine. Pooled plasma 
from healthy human subjects with known apo E  level, was used as a 
standard.
Human apo E and mouse Ldlr m R N A  measurements in the liver. 
Total RNA was isolated from liver using the R N A Z O L  procedure 
(Cinna/Biotecx, Houston, TX). RNA samples (10 jxg per lane) were 
separated by electrophoresis through a denaturing agarose gel (1.2%
wt/voJ) containing 7.5% form aldehyde and transferred to a nylon 
membrane (Hybond N + ; A m ersham  Corp., Arlington Heights, IL) 
according to the m anufacturer’s recommendations. For analysis of 
the mouse Ldlr  expression, po lyA + R N A  was isolated using the 
PoIyATtract m R N A  isolation kit (Prom ega Corp., Madison, WI). 
Blots were subsequently hybridized with 32P-Jabeled probes of human 
apo E  cDNA (10), mouse Ldlr  cD N A  (mLDLRc90) (11), and rat 
glyceraldehyde-3-phosphate dehydrogenase (G A PD H ) cD N A  at 
55°C in a solution containing 50% formamide. The intensity of the 
hybridization signal was quantified with a Phosphorlmager (Molecu­
lar Dynamics Inc., Sunnyvale, CA). The am ounts of APOE*3-Leiden 
and LDL receptor m R N A  were related to the level of G APD H  mRNA.
Hormone treatment. HFC-fed male and female transgenic mice
14 wk of age were injected subcutaneously along the back every 14 d 
with testosterone decanoate or estradiol decanoate dissolved in ara- 
chis oil. Blood sampling and serum  analysis were performed before 
and after 28 d of horm one treatm ent as described above. Estradiol 
decanoate and testosterone decanoate were a kind gift from Drs. H. 
Verheul and F. Deckers, Organon International bvM Oss, The N eth­
erlands.
In vivo hepatic triglyceride production. A fter a 12-h fasting pe­
riod mice were injected intravenously with Triton WR1339 (500 mg/ 
kg body wt) (12) using 15% (wt/vol) T riton solution in 0.9% NaCl. A t 
0, 45, and 90 min after injection blood samples were drawn and ana­
lyzed for triglycerides as described above. Production of hepatic tri­
glyceride was calculated from the slope of the curve and expressed as 
mmol/h per kg body wt. For calculation of mouse total serum volume 
we used the equation: serum volume  =  0.33 X body wt (13).
Isolation and labeling o f  V L D L . Blood was collected from six to 
eight fasted transgenic or 15-20 fasted nontransgenic mice. Sera were 
pooled and ultracentrifuged to obtain the V LD L fraction (d < 1.006 
g/ml). V L D L  cholesterol and triglyceride w ere determined enzymati­
cally as described above, and V L D L  protein was determined using 
the method of Lowry e t al. (14). To determ ine apo B content of the 
VLDL, some 25 jig of V L D L  protein was subjected to a 4-20% gradi­
ent SDS-PAGE. After staining with Coomassie brilliant blue R and 
destaining in 30% methanol/10% acetic acid the gels were scanned 
using an HP ScanJet Plus, Hewlett Packard, Santa Clara, CA, and the 
am ount of apo B (100+48) relative to total protein was calculated. 
The percentage of total apo B ranged from 20 to 40% of total VLDL 
protein. V LD L was radiolabeled with ,25I by the iodine monochloride 
method (15). The fraction of l2ST-labe! present in apo B was deter­
mined by isopropanol precipitation (16,17) and ranged from 30 to 65%.
In vivo removal o f 125¡-labeled V L D L -apo  B. Fasted mice were 
intravenously injected with 0.2 ml of 0.9% NaCl containing BSA 
(1 mg/ml) and 10 |xg of 125f-labeled VLDL. Blood samples of ^  25 (xl 
were collected from the tail vein at t =  1, 3, 5, 10, 30, 60, and 90 min 
after injection. The serum  content of l25I~labeled apo B was measured 
by isopropanol precipitation followed by counting !2SI-label. A bi­
exponential model was used to  estimate the area under the I25I-apo B 
decay curve and subsequent calculation of VLDL-apo B kinetics. 
V LD L secretion rate was calculated from V LD L fractional catabolic 
rate  and serum apo B pool. Since >  85% of serum apo B and triglyc­
erides were associated with the d <  1.006 lipoprotein fraction, we de­
termined the serum apo B pool by measuring serum triglyceride lev­
els 48 h before injection and the apo B to triglyceride ratio in the 
isolated d <  1.006 lipoproteins (V LD L) of mice from the same group 
(autologous). Serum triglycerides on 48 h before injection were 
^  20% higher as compared to serum triglyceride levels a t the end of 
the turnover experiment. However, this decreasing effect was similar 
for all mice injected.
Results
Effect o f  age, gender, and diet on serum lipid and lipoprotein 
levels. The increase in body weight with age for male and fe­
male transgenic and nontransgenic mice is shown in Fig* 1. No



















Figure 1. Age- and sex-dependent 
body weight. Body weight changes 
due to the increase in age were fol­
lowed over time in male (squares) 
and female (circles) mice fed an 
SRM-A diet (A) or an HFC diet 
(B). All groups contain at least 13 
mice, which were weaned at day 
25± i. Body weight was determined 
after an overnight fast. Values are 
expressed as m ean±S E  (error bar 
not visible when SE <  symbol size). 
Closed symbols, APOE*3-Leiden 
transgenic mice; open symbols, con­
trol mice.
difference in growth rate was observed between transgenic 
and control mice and between both diets administered. At an 
early age, the gain in body weight was more rapid than at later 
age and more pronounced for male than for female mice.
Fig. 2 (A-C) shows the effect of age on serum cholesterol 
(¿4), triglyceride (B ), and the apo E3-Leiden protein levels (C) 
for SRM-A fed mice. At weaning, transgenic and nontrans­
genic animals showed comparable levels of serum cholesterol 
and triglycerides. Transgenic animals showed a rapid signifi­
cant increase (P <  0.01) in both serum cholesterol and triglyc­
erides with a maximum around 45 d of age. This postweaning 
increase was more pronounced for male than for female trans­
genic mice. Serum apo E3-Leiden levels also displayed a sig­
nificant increase (P <  0.01) in levels directly after weaning. 
However sex differences were not observed during this period. 
At an early age nontransgenic animals also showed an increase 
for both serum cholesterol and triglyceride levels, however this 
increase was less pronounced as compared to transgenic animals.
The increases at an early age in transgenics in levels of cho­
lesterol, triglycerides, and apo E3-Leiden appeared to be tran­
sient. After 150 d of age, serum cholesterol and triglycerides 
had decreased to almost basal levels of about 2.5 and 2.0 
mmol/liter, respectively. At this age females had higher levels 


























Figure 2.  Age- and sex-dependent 
serum cholesterol, triglycerides and 
apo E3~Leiden levels. Mice were fed 
an SRM-A diet (A-C) or an HFC 
diet (D~F)t Serum cholesterol (A 
and D), triglycerides (B  and E), and 
apo E3-Leiden levels (C and F) 
were followed in time in male 
(squares) and female (circles) 
APOE*3~Leiden and control mice. 
All groups contain at least 13 mice, 
which were weaned at day 25 ±1. 
Blood samples were drawn by tail 
bleeding after an overnight fast. 
Vertical bars represent standard e r ­
ror of the means. Statistical analysis 
was performed using the repeated 
measuring A N O V A  to determine 
the influence of age and gender on 
cholesterol, triglycerides and apo 
E3-Leiden levels. Closed symbols, 
APOE3-Leiden mice, open sym­
bols, control mice.
1186 Van Vlijmen et al
males showed significantly higher apo E3-Leiden levels than 
males (40 vs 18 mg/dl).
Fig. 2 (D-F) shows the serum cholesterol, triglyceride, and 
apo E3-Leiden levels after feeding a cholesterol-rich HFC 
diet. The time course profiles for serum triglycerides (E) re­
sembled those observed after regular SRM-A feeding (.B), 
whereas after feeding HFC the respective levels of apo E3- 
Leiden (F) were about twice as high as during SRM-A feeding 
(C). At an early age, serum cholesterol levels (D) were two to 
threefold higher as compared to SRM-A feeding. In contrast 
to SRM-A feeding, HFC feeding led to prolonged elevated 
levels of cholesterol, although for males a slight decrease in se­
rum cholesterol levels to about 7.0 mmol/liter was observed at 
a later age.
Nontransgenic animals at an early age also showed in­
creased levels of cholesterol and triglycerides after feeding 
HFC diet, but to a much smaller extent as compared to trans­
genic animals. In contrast to transgenic mice, nontransgenic 
male mice at a later age had slightly higher lipid levels as com­
pared to nontransgenic females.
Fig. 2 suggests that the effect of HFC feeding on lipid levels 
at an early age is a result of both age, as observed during SRM-A 
feeding, and an additional dietary component To study the ef­
fect of HFC feeding on serum lipid levels solely, mice of 200 d 
of age and fed a SRM-A diet were switched to the HFC diet. 
As illustrated in Fig. 3 A , transgenic animals displayed an in­
crease in serum cholesterol levels but less pronounced than at 
an early age (as shown in Fig. 2), and again the females were 
more responsive than the males (up to 7.5 and 5.5 mmol/liter, 
respectively). Remarkably, serum triglycerides (B) showed 
only a small and transient increase, whereas apo E3-Leiden 
levels (C) strongly increased from 7 to 26 and from 30 to 90 for
Figure 3. The effect of 
H F C  feeding at a later 
age. Serum cholesterol 
(A), triglycerides (B ), 
and apo E3-Leiden (C) 
were followed in time 
for male (squares) and 
female (circles) mice 
which switched from 
SRM -A diet to H FC at 
200 d of age. All groups 
contain at least '13 mice. 
Blood samples were 
drawn by tail bleeding 
after an overnight fast. 
VerLical bars represent 
SEMs. Statistical analy­
sis was performed using 
the repeated measuring 
A N O V A  to determine 
the influence of age 
and gender on choles­
terol, triglycerides and 
apo E3-Leiden levels. 
Black symbols, APOE3- 




























males and females, respectively. In nontransgenics, serum cho­
lesterol levels were much less severely elevated after feeding 
HFC diet at a later age, whereas serum triglyceride levels were 
not affected at all.
The results described above clearly indicate that serum lip­
ids in transgenic mice are affected by age, nutrition, and gen­
der. To investigate in which lipoprotein classes these changes 
in serum lipids mainly occur, we analyzed lipoprotein profiles 
by FPLC gelpermeation chromatography using a Superose 6B 
column and calculated the distribution of cholesterol among 
VLDL/LDL and HDL-sized lipoproteins, respectively. Feed­
ing both an SRM-A or HFC diet, the major changes in serum 
cholesterol were confined to the VLDL/LDL-sized fractions. 
In addition, the higher serum cholesterol levels in females as 
compared to males during the diets at a later age are also con­
fined to this lipoprotein fraction (results not shown).
We further investigated the effect of age and gender on hy­
perlipoproteinemia in the A FO E:f!3-Leiden mice, separately. 
For investigating the effect of age we used only young (45 d of 
age) and older (> 100 d of age) SRM-A fed male mice, since 
the effect of age on serum iipid levels was more pronounced in 
male than in female mice. For studying the effect of gender we 
used older male and female mice (> 100 d) fed an HFC diet, 
since the effect of gender on hyperlipoproteinemia was more 
pronounced in older than in young mice.
Effect o f  age on V LD L metabolism in vivo. Our previous 
study has shown that the level of hyperlipidemia corresponds 
to the expression level of the APOE*3-Leiden gene (8, 9). To 
study whether the transient accumulation of VLDL/LDL sized 
lipoproteins at an early age on either diet is due to transient 
higher expression levels of the transgene, we determined 
APOE*3-Leiden mRNA in the liver by Northern blotting. 
Livers of mice with maximum hyperlipidemia (45 d of age) 
were compared to older mice (>  100 d of age). From the re­
sults presented in Table I, it is obvious that no significant dif­
ferences in E3-Leiden mRNA levels in the liver were observed 
between young and old male mice when fed a SRM-A diet. 
Feeding HFC diet resulted in slightly but not significantly ele­
vated levels of E3-Leiden mRNA as compared to SRM-A 
feeding. These results indicate that the age-dependent serum 
lipid and apo E3-Leiden protein levels were not related to 
changes in expression of the transgene.
To investigate whether the effect of age on serum levels of
Table I. Age- and Diet-dependent APOE*3-Leiden m RNA  
Expression in Mouse Liver
Sex Age SRM-A HFC
(I %
Males 45 100.0±19.0 118.2±12.6
> 1 0 0 80.9±5.6 117.2±24.7
APOE* 3-Leiden RNA in liver was quantified for young (45 d of age) 
and old male mice (>  100 d of age). After an overnight fast, mice were 
anesthesized, liver was excised, and APOE*3-Leiden RNA was quanti­
fied as described in methods section. Mice were fed SRM-A diet or 
HFC diet. A P O E ^ -L e id en  RN A  concentrations are relative to internal 
standard G A PD H  and expressed as a percentage of male (45 d of age) 
SRM-A fed group. Values are the m ean±SD  of three to five mice. Val­
ues are not statistically different (P <  0.05; using nonparametric Mann- 
Whitney test).
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VLDL/LDL-lipoproteins was related to changes in endoge­
nous VLDL production by the liver we determined the in vivo 
hepatic VLDL-triglyceride production rate. Therefore, young 
male mice of 45 d of age and old male mice (> 100 d of age), 
both transgenic and nontransgenic, were injected with Triton 
WR1339 and the increase in serum triglycerides after injection 
was determined. As presented in Table II, VLDL-production 
rates were significantly affected by age, young male mice dis­
playing about 50% higher VLDL-triglyceride production rate 
than older mice irrespective of the presence of the APOE*3- 
Leiden transgene.
To investigate whether the effect of age on serum levels of 
VLDL/LDL-lipoproteins was also due to changes in VLDL 
clearance rate, in vivo VLDL turnover studies were per­
formed. Young male transgenic and nontransgenic mice of 45 
d of age and old male transgenic mice (> 100 d of age), were 
injected with 10 jxg of autologous l25I-labeled VLDL, and the 
125I-apo B disappearance from the circulation was determined* 
As illustrated in Fig. 4 A  and presented in Table III, VLDL 
fractional catabolic rate (FCR) was clearly affected by trans­
gene expression. Young transgenic mice displayed a signifi­
cantly lower VLDL-FCR as compared to young nontransgenic 
mice. In contrast, no effect of transgene expression on VLDL 
secretion rate (VLDL-SR) was observed, indicating that the 
higher serum lipid levels in transgenic mice as compared to 
nontransgenic mice were due to an impaired VLDL clearance 
rate, as expected.
An age-related change in VLDL-FCR was not observed as 
young and old transgenic mice displayed comparable VLDL- 
FCR (Fig. 4 B and Table III), In contrast, a strong and signifi­
cant effect of age on VLDL-SR is observed (Table III, 4.24 
versus 2.45 fig apo B/h per g body wt in young and oid trans­
genic mice, respectively). This decreasing VLDL-SR with age 
corresponds with the observed lower hepatic VLDL-triglycer­
ide production rate as determined by the Triton method (Ta­
ble II).
Effect o f  sex hormones on serum lipid levels and on VLDL  
metabolism in vivo. Maximal gender related differences in 
lipid levels in APOE*3-Leiden mice were observed at a later 
age (>  100 d) after feeding HFC. Thus, to investigate these 
gender related differences, older mice on an HFC diet were 
treated with either testosterone or estradiol. Mice were in-





45 0.180 ±0.021* 0.150 ±0.011*
>  100 0.112±0.017 0.102±0.018
After an overnight fast SRM-A fed male mice were injected with Triton 
WR1339 (sec Methods section). The serum triglycerides were deter­
mined just before injection (0 min) and at 45 and 90 min after Triton in­
jection. Production of hepatic triglyceride rate was calculated from the 
slope of the curve and is expressed as mmol/h/kg body weight. Values 
are expressed as m ean±SD (n =  4). *P <  0.05, indicating the difference 
between mice of 45 d of age and mice of >  100 d of age, using nonpara- 
metric Mann-Whitney test.
A B
time after injection (min.)
Figure 4. The effect of age on VLDL-apo B removal. SRM-A fed 
male mice were injected with autologous 125I-labeled VLDL, 2 5  jjlI of 
blood was drawn at each time point and l25I-apo B radioactivity of the 
serum sample was measured. Values are the m ean±SD  of seven 
mice, Curves were calculated from the mean data using a bi-exponen­
tial curve fit model.
jected subcutaneously either a physiological or a pharmacolog­
ical dose of either hormone. As presented in Table IV, in male 
mice, treatment with estradiol resulted in a significant increase 
in serum triglyceride levels, whereas treatment with testoster­
one decreased serum cholesterol levels, although not signifi­
cantly. Also for female mice, treatment with estradiol resulted 
in significantly increased serum triglyceride levels, whereas 
treatment with a pharmacological dose of testosterone signifi­
cantly decreased both serum cholesterol and triglyceride levels.
To investigate in which lipoprotein classes these changes in 
serum lipid levels mainly occur, we generated lipoprotein pro­
files by FPLC gelpermeation chromatography using Superose 
6B. In male mice (Fig. 5 A) treatment with estradiol resulted in 
a slight dose-dependent decrease of HDL cholesterol, whereas 
an increase of cholesterol in the VLDL-sized lipoprotein frac­
tions is observed, thus, leading to an unaffected total serum 
cholesterol level as presented in Table IV. The decrease in se-
Table III. Age-dependent VLDL-apoB Fractional Catabolic 
Rates and Secretion Rates
Mice Age FCR SR
d poois/h fig apoB/h/g body wt
nontransgenics 45 3.94±1.22 3.67 ± 1 -81
transgenics 45 1.45 ±0.34* 4.24±0.95
transgenics > 1 0 0 2.00 ±1.23 2.45+1.05*
After an overnight fast SRM-A fed male mice were injected with 10 (xg 
of autologous 125l-labeled V LD L protein. 125l-apo B disappearance from 
the circulation was determined and FCR and SR were calculated (see 
Methods). Values are expressed as mean±SD (n = 7). *P <  0.05, indi­
cating the difference between transgenic and nontransgenic mice of age 
45 d, <  0.05, indicating the difference between transgenic mice of 45 
d of age and >  100 d of age, using nonparametric Mann-Whitney test.
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Table IV. Serum Lipid Concentrations after 4 wk o f Hormone 
Treatment o f  AP0E*3-Leiden Transgenic Mice




Estradiol decanoate 5.47±0.66 3.06±0.60*
(20 (jug/mouse) 
Estradiol decanoate 6.71 ±0.32 4.57±0.65*
(100 fxg/mouse) 
Testosterone decanoate 5.45±0.32 2.49±0.65
(250 (jug/mouse) 
Testosterone decanoate 5.18±0.75 2.66±0.44
Females
(1250 fxg/mouse) 
Placebo 9.46 ±1.50 3.36±0.79
Estradiol decanoate 10.70±1.72 4.62±0.64*
(20 |xg/mouse) 
Estradiol decanoate 10.69 ±1.58 5.09± 0.735i:
(100 (jig/mouse) 
Testosterone decanoate 8.10±1.01 2.47 ±0.55
(250 jxg/mouse) 
Testosterone decanoate 6.64±1.15* 2.2ö±0.33*




% o f control
Placebo 100.0±22.7 100.0±9.6
Estradiol decanoate 100.5 ±19.6 98.8±12.5
(20 fxg/mouse)
Estradiol decanoate 74.8 ±26.9 105.4 ±3.4
(100 (xg/mouse)
Testosterone decanoate 74.1 ±19.4* 94.7 ±13.2
(250 fxg/mouse)
Testosterone decanoate 65.3±15.5* 83.4±8.9*
(1250 (j,g/mouse)
(1250 |ui,g/mouse)
mRNA levels were measured in livers of mice treated* as described, for 
4 wk. mRNA concentrations were relative to internal standard G A PD H  
and expressed as a percentage of placebo group (control) of the same 
sex. Values are the m ean±SD  of five mice. *P <  0.05, indicating the dif­
ference between hormone and placebo treated groups of mice of the 
same sex, using nonparametric Mann-Whitney tests.
TC, total cholesterol; TG, triglyceride. Total cholesterol and triglycer­
ide values are the mean scrum levels±SD of five APOE*3-Leiden 
transgenic mice per group. *P < 0.05, indicating the difference between 
hormone and placebo treated groups of mice of the same sex, using 
nonparametric Mann-Whitney tests.
rum cholesterol and triglycerides levels observed after testos­
terone treatment of female mice was confined to VLDL/LDL 
sized-lipoprotein fractions (Fig. 5 B).
To investigate whether changes in lipid levels after hor­
mone treatment were initiated by changes in transgene expres­
sion, we also determined APOE*3-Leiden mRNA levels in 
the liver of both HFC-fed male and female mice, treated with 
either testosterone or estradiol. As presented in Table V, for
A B
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Figure 5. Distribution of serum cholesterol among lipoprotein frac­
tions after hormone treatment. Lipoprotein fractions were separated 
by permeation chromatography using a 25-ml Superose 6B column as 
described in Methods. Lipoprotein profiles are shown for male (A) 
and female transgenic mice (B ) which were treated with estradiol 
decanoate or testosterone decanoate, respectively. Each run is per­
formed with a pool of at least five mice of the same group. Fraction 
numbers 5-15 and 16-30 correspond to  V L D L /L D L  and HDL, re­
spectively. Solid, dashed, and dotted lines represent mice treated with 
placebo, physiological dose, and pharmacological dose of hormone, 
respectively (see Table IV).
both males and females, estradiol administration had no signif­
icant effect on the expression of the APOE*3-Leiden gene. In 
contrast, administration of testosterone resulted in a signifi­
cant lowering of APOE*3-Leiden mRNA levels for both male 
and female mice. In a parallel experiment untreated male mice 
(placebo) displayed significantly lower expression of the 
A POE *3-Leiden transgene than untreated female mice (69.0±
14.5 versus 100±'13.2%). Since hepatic LDL receptors are 
known to be regulated by estradiol administration, at least in 
rats (18-20) and humans (21), we also determined LDL recep­
tor mRNA levels in estradiol-treated female mice. In female 
mice hepatic Ldlr mRNA levels were not affected by estradiol 
administration (100±25.3 versus 102±25.9% for placebo and 
estradiol treated animals, respectively).
We investigated whether the changes in serum levels of 
VLDL/LDL-sized lipoproteins upon sex hormone administra­
tion were related to a concurrent change in hepatic VLDL 
triglyceride production rate. As presented in Table VI, pla- 
cebo-treated female mice displayed a significantly higher 
VLDL-triglyceride production rate as compared to placebo- 
treated male mice. VLDL-triglyceride production rate in fe­
male mice did not change upon testosterone treatment, 
whereas a 20% increase in VLDL-triglyceride production rate 
was observed in males after estrogen treatment.
To evaluate whether sex hormones were also influencing 
the plasma clearance rate of VLDL, we performed in vivo 
VLDL turnover studies. Placebo-treated male and female 
mice displayed comparable VLDL-FCR’s (Table VII). As il­
lustrated in Fig. 6 A  and presented in Table VII, VLDL-FCR 
in males decreased significantly after estrogen treatment, 
whereas a significant increase in VLDL-FCR was observed in 
females after testosterone treatment (Fig. 6 B; Table VII). Op­
posite effects were observed for VLDL-SR: VLDL-SR in male 
mice increased after estrogen treatment, whereas a slight de­
crease in VLDL-SR is observed in female mice after testoster­
one treatment. In addition, placebo-treated female mice dis­
played a higher VLDL-SR as compared to placebo treated
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Table VI. In Vivo Hepatic VLDL-Triglyceride Production 




% o f placebo treated mates
Placebo 100.0+33.0 135.6±33.0*
Estradiol decanoate 119.6+38.6 ND
(100 |jLg/mouse)
Testosterone decanoate ND 135.1+32.5
(1250 (jug/mouse)
After an overnight fast hormone treated APOE*3-Leiden transgenic 
mice were injected with Triton WR1339 (see Methods). The serum tri­
glycerides were determined just before injection (0 min) and at 45 and 
90 min after Triton injection. Hepatic VLDL triglyceride production 
rate was calculated from the slope of the curve and is expressed as 
mmol/h/kg body wt. Values are the m ean±SD, Since two independent 
experiments are combined to increase the number of animals per groups 
(n = 14-16) values are expressed as a percentage of the hepatic VLDL 
triglyceride production in placebo treated male mice in the same experi­
ment. *P < 0.05, indicating the difference between male and female 
mice, using nonparametricM ann-W hitney test. ND; not determined.
male mice. Although these effects on VLDL-SR were not sig­
nificant, these changes in VLDL-SR correspond with changes 
upon hormone treatment in serum lipid levels (Table IV) and 
in hepatic VLDL-triglyceride production rate (Table VI).
Discussion
In the present study we showed that hyperlipidemia in 
APOE*3-Leiden mice was severely affected by age (Figs. 2 
and 3). At early age in the APOE*3-Leiden mice an enhanced 
production of hepatic VLDL was observed, whereas the 
plasma clearance of VLDL was not age dependent (Tables II 
and III). Apparently, since APOE*3-Leiden mice are unable 
to efficiently remove VLDL remnants from the circulation
Table VII, VLDL-apoB Fractional Catabolic Rates and 
Secretion Rates after 4 wk o f  Hormone Treatment o f  
APOE*3-Leiden Transgenic Mice
Sex Treatment FCR SR
fig apoB/h/g
pools/h body ivt
Males Placebo 1.06 ±0.27 1.65±0.34
Estradiol decanoate 0.68+0.17* 1.94 ±0.48
(100 jig/mouse)
Females Placebo 1.11+0.20 2.13 ±0.79
Testosterone decanoate 1.46±0.42* 1.94±0.41
(1250 |ig/mouse)
After an overnight fast HFC fed mice were injected 10 jig of autologous 
,25I-labeled VLDL protein. 125I-apoB disappearance from circulation 
was determined and FCR and SR were calculated (see Methods). Val­
ues are the m ean±SD of 4-6 mice per group. *P <  0.05, indicating the 
difference between hormone and placebo treated groups of mice of the 
same sex* using nonparametric Mann-Whitney tests.
A B
time after injection (min.)
Figure 6. The effect of 4 wk of hormone treatm ent on VLDL-apo B 
removal. H FC fed transgenic mice (>  100 d of age) were injected 
with autologous l25l-labeled VLDL, Some 25 p,l of blood was drawn 
at each time point and 125I-apo B radioactivity of the serum sample 
was measured. Values are the m ean±SD  of four to six mice. Curves 
were calculated from mean data using a bi-exponential curve fit 
model,
(Fig. 4 A  and Table III), the extra supply of newly synthesized 
hepatic VLDL, as occurring during rapid growth, is primarily 
responsible for the enhanced accumulation of these lipopro­
teins in the plasma at young age. Increased VLDL production 
rate has also been reported to occur in young rapidly growing 
rats, due to a stimulation of the hepatic triglyceride synthesis 
by growth hormone (22,23). In adult humans VLDL synthesis 
is also known to be stimulated upon body weight gain. Similar 
to APOE:iî3-Leiden mice, in humans carrying mutant APOE 
alleles, like APOE*3-Leiden, APOE*2(Lysl46-»Gln) and the 
APOE*2(Argl58—>Cys), high body weight and body weight 
gain are strong aggravating factors in the accumulation of 
VLDL remnants (familial dysbetalipoproteinemia) (1, 6,24).
APOE*3'-Leiden transgenic mice displayed a marked ef­
fect of gender on the expression of hyperlipidemia (Figs. 2 and 
3). Estrogens increase serum lipid levels, whereas testosterone 
showed the opposite effect (Table IV, Fig. 5). Previously, we 
reported that in APOE*3-Leiden mice the level of serum lip­
ids is positively correlated with the level of the expression of 
the transgene in the liver (9). In the present study we found 
that expression of the APOE^3-Leiden gene results in a re­
duced clearance rate of VLDL, whereas the production of 
VLDL was not affected by the presence of the transgene (Ta­
ble III). Thus, the observation that testosterone administration 
results in a reduced expression of the APOE*3-leiden trans­
gene in the liver (Table V) can explain why testosterone ad­
ministration resulted in lower serum VLDL/LDL lipoprotein 
levels, i.e., testosterone increases the clearance rate of VLDL, 
without an effect of testosterone on VLDL production rate 
(Table VI and VII). The reason for the effect of testosterone 
on the expression of the transgene is at present subject to spec­
ulation, Transgene expression was not affected by estrogen ad­
ministration (Table V) and thus cannot explain the observed 
reducing effect of estrogen on VLDL clearance (Table VII).
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We present evidence that the increased serum lipid levels ob­
served in females, and after estrogen administration in males 
(Table IV) can, at least partly, be explained by a relatively high 
rate of VLDL production (Table VI and VII).
The respective effects of both steroid hormones on the se­
rum lipids and lipoprotein profile, hepatic VLDL triglyceride 
production and VLDL-apo B secretion are in line with the ob­
served differences in lipid levels between untreated male and 
female APOE*3-Leiden mice. However, although both tes­
tosterone and estrogen treatment displayed considerable but 
opposing effects on VLDL clearance rate, differences in 
VLDL clearance were not found between untreated male and 
female mice. Similarly, although estrogens decreased VLDL 
clearance rate in males, the only significant difference between 
untreated males and females was increased VLDL production 
rate in females. These observations suggest discrepancies in 
the overall observed gender effect. However, in untreated 
males and females endogenous sex hormones form only part 
of the whole set of factors determining the final phenotype. 
The use of castrated males and ovariatectomized females in­
stead of the respective sex hormone injected animals might 
have avoided these apparent discrepancies. In this study, addi­
tion of (supra) physiological doses of exogenous sex hormones 
was carried out only to evaluate the direction of the effect 
rather than that it aimed to extrapolate the effect to the basal 
in vivo situation in a quantitative sense.
Clearly, estrogens play an important role in mediating the 
gender differences observed in APOE*3-Leiden mice. The es­
trogen-mediated stimulation of hepatic VLDL production is 
well documented for humans (25) and rats (26) and suggests 
estrogen to be a risk factor for FD. Paradoxically, in humans 
FD is more prevalent in men than in women (1) and estrogen- 
replacement therapy is frequently used in reducing the expres­
sion of FD (27). Obviously, in humans estrogens play a protec­
tive rather than an aggravating role in the accumulation of 
VLDL remnant lipoproteins. An explanation for this benefi­
cial effect of estrogens in humans is commonly assumed to be 
the fact that estrogens stimulate the expression of hepatic LDL 
receptors (18-21). The fact that an increase in hepatic LDL re­
ceptor mRNA upon estrogen treatment does not occur in 
hamsters and mice (28-30) including the present APOE*3- 
Leiden transgenic mice, could explain the opposing effects of 
estrogen in humans and mice regarding the accumulation of 
remnants.
It could be possible that in mice hepatic LDL receptor ac­
tivity is less susceptible to regulation than it is in humans. This 
is also supported by the observations that feeding C57BL/6J 
mice a high fat/cholesterol diet results in downregulation of 
HMG-CoA reductase activity whereas LDL receptor expres­
sion is relatively unaffected (31, 32). We hypothesize that an 
increased hepatic VLDL production increases the hepatic 
demand for cholesterol, but in mice this is not followed by 
upregulation of hepatic LDL receptors like in humans. Con­
sequently, in APOE*3-Leiden mice, which are unable to effi­
ciently metabolize hepatic lipoproteins, the increase in VLDL 
production upon the administration of estrogen will not be 
compensated by a simultaneous upregulation of LDL recep­
tors and, thus, will lead to an extra accumulation of these lipo­
proteins in the plasma.
For the APOE*3-Leiden mice used in the present study> 
the APOC1 gene was included to be sure to have included an 
element that mediates liver-specific expression of the apo
E gene. Recently, we have generated transgenic mice express­
ing the APO E* 3-Leiden gene without the human APO Cl 
gene but containing the hepatic control region mediating liver 
expression. These mice have comparable expression of the 
APOEii:3-Leiden transgene on the level of mRNA and on the 
level of serum apo E protein. In addition, these mice display 
similar diet-induced hyperlipoproteinemia and also show a 
similar effect of age and gender on the hyperlipidemic pheno­
type (results not shown). Hence, a role for the human APOC1 
gene in inducing the age- and sex-dependent hyperlipidemic 
phenotype can be excluded.
Transgenic mice expressing the defective A PO E (A rgll2, 
Cys'142) variant, also display diet-induced elevated levels of 
plasma cholesterol and triglycerides due to the accumulation 
of remnant lipoproteins (33,34). However, in these mice a sim­
ilar gender- and age-related effect on plasma lipid levels has 
not been reported. On the contrary, in heterozygous apo E-defi­
cient mice elevated plasma Jipid levels in females as compared 
to males have also been observed, after being fed severe cho­
lesterol-rich diets (35). Such a gender effect has not been re­
ported (35-39) in homozygous apo E deficient mice, either due 
to the extreme phenotype of these mice under normal condi­
tions or the absence of apo E itself.
In this study, we have shown that age- and gender-related 
changes in serum lipid levels of APOE*3-Leiden mice at least 
in part were related to mild changes in hepatic VLDL produc­
tion. These results are consistent with our previous study (9) 
showing that the serum lipid levels in A PO Esii3-Leiden mice 
are also highly responsive to sucrose feeding which is known to 
increase hepatic lipogenesis and thereby the production and 
secretion of VLDL triglyceride by the liver (7,40,41). We con­
clude that introducing a defective apo E, like in the APOE*3- 
Leiden transgenic mice, leads to a high responsiveness of the 
serum lipid levels to relative mild changes in chylomicron and 
VLDL production rate. Consequently, this animal model can 
easily be used for studying the effect on plasma lipid levels of 
(subtle) environmental factors, like nutrition and drugs that 
are supposed to modulate VLDL production in the liver or 
lipid absorption and chylomicron production in the intestine. 
In addition, our results strongly sustain the hypothesis that in 
carriers of mutant apo E alleles the production rate of both 
liver and intestinal lipoproteins are important determinants of 
the clinical expression of familial dysbetalipoproteinemia.
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